(Q39116695)

English

Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts

scientific article published on 21 March 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 September 2017

Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts (English)

1 reference

Europe PubMed Central

9 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

7

object named as

Lars A Akslen

1 reference

Europe PubMed Central

9 September 2017

Ingrid Susann Gribbestad

8

object named as

Ingrid S Gribbestad

1 reference

Europe PubMed Central

9 September 2017

Gunhild M. Mælandsmo

6

object named as

Gunhild M Mælandsmo

1 reference

Europe PubMed Central

9 September 2017

Olav Engebraaten

5

object named as

Olav Engebraaten

1 reference

Europe PubMed Central

9 September 2017

4

object named as

Anna Bofin

1 reference

Europe PubMed Central

9 September 2017

Evita Maria Lindholm

3

object named as

Evita M Lindholm

1 reference

Europe PubMed Central

9 September 2017

Siver Andreas Moestue

1

object named as

Siver A Moestue

1 reference

Europe PubMed Central

9 September 2017

2

object named as

Else M Huuse

1 reference

Europe PubMed Central

9 September 2017

publication date

21 March 2013

1 reference

Europe PubMed Central

9 September 2017

Journal of Magnetic Resonance Imaging

1 reference

Europe PubMed Central

9 September 2017

38

1 reference

Europe PubMed Central

9 September 2017

5

1 reference

Europe PubMed Central

9 September 2017

1043-1053

1 reference

Europe PubMed Central

9 September 2017

Isolation of a tumor factor responsible for angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Anticancer strategies involving the vasculature

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the 'normalization' window of the tumor vasculature

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Dynamic contrast-enhanced MRI in the diagnosis and management of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Predicting and monitoring cancer treatment response with diffusion-weighted MRI.

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights.

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo HR MAS, and in vivo 1H MRS.

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age.

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Vascular proliferation is increased in basal-like breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.24079

21 January 2018

Identifiers

10.1002/JMRI.24079

1 reference

Europe PubMed Central

9 September 2017

1 reference

Europe PubMed Central

9 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39116695&oldid=1858982950"